Bristol-Myers Squibb Company
AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS

Abstract:

The present disclosure relates to amorphous and crystalline forms of (R)-N-(4-chlorophenyl)-2-(1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)prop- anamide and its salts and hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.